Vascepa to Accelerate Lipoprotein Uptake and Elimination
NCT03885661
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Lipid Disorder
Triglycerides High
Dyslipidemias
Interventions
DRUG:
Icosapent Ethyl 1000 MG [Vascepa]
Sponsor
University of Pennsylvania
Collaborators
[object Object]